Five Prime Therapeutics, Inc.
FPRX
FPRX was delisted on the 15th of April, 2021.
114 hedge funds and large institutions have $167M invested in Five Prime Therapeutics, Inc. in 2019 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 39 increasing their positions, 31 reducing their positions, and 21 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 31
14% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 21
1% more funds holding
Funds holding: 113 → 114 (+1)
61% less capital invested
Capital invested by funds: $424M → $167M (-$257M)
100% less call options, than puts
Call options by funds: $1K | Put options by funds: $243K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| 1 |
Man Group
London,
United Kingdom
|
+$5.43M |
| 2 |
Renaissance Technologies
New York
|
+$5.1M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$4.96M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$3.32M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.31M |
Top Sellers
FPRX Hedge Fund Activity: Q2 2019 in Review
114 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Five Prime Therapeutics, Inc. (FPRX) for Q2 2019, worth a combined $167M — down 61% from $424M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new FPRX positions and 21 closed out — a net gain of 3 holders — while 39 added to existing stakes and 31 trimmed.
The largest buyer was Man Group, adding an estimated $5.43M. The largest seller was Fidelity Investments, cutting an estimated $18.1M.
- 114 institutional investors held Five Prime Therapeutics, Inc. (FPRX) as of Q2 2019, up from 113 in Q1 2019.
- Funds reported $167M of Five Prime Therapeutics, Inc. stock for Q2 2019, down 61% quarter-over-quarter.
- 24 funds opened new Five Prime Therapeutics, Inc. positions in Q2 2019 and 21 closed out, a net change of +3 holders.
- The largest Five Prime Therapeutics, Inc. buyer in Q2 2019 was Man Group, an estimated $5.43M added.
- The largest Five Prime Therapeutics, Inc. seller in Q2 2019 was Fidelity Investments, an estimated $18.1M sold.
Based on aggregated 13F filings for Q2 2019.